At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 34 enrolled
Drug / intervention
Topiramate or Placebodrug
Likely dose
Topiramate or Placebo 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder
In Brief
A Early Phase 1 clinical trial evaluating Topiramate or Placebo for Sleep-Related Eating Disorder. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The purpose of the study is to learn about the safety and effectiveness of oral (taken by mouth) topiramate in treating Sleep-Related Eating Disorder (SRED).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep-Related Eating Disorder
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionNov 2018
TodayJul 2026
First PostedFeb 4, 2008
Enrollment StartJan 1, 2008
Primary CompletionNov 29, 2018
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 18.4 years ago
Interventions
Topiramate or Placebodrug
25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules